PMID- 29663841
OWN - NLM
STAT- MEDLINE
DCOM- 20190207
LR  - 20211204
IS  - 1549-781X (Electronic)
IS  - 1040-8363 (Linking)
VI  - 55
IP  - 4
DP  - 2018 Jun
TI  - Novel heart failure biomarkers: why do we fail to exploit their potential?
PG  - 246-263
LID - 10.1080/10408363.2018.1460576 [doi]
AB  - Plasma biomarkers are useful tools in the diagnosis and prognosis of heart 
      failure (HF). In the last decade, numerous studies have aimed to identify novel 
      HF biomarkers that would provide superior and/or additional diagnostic, 
      prognostic, or stratification utility. Although numerous biomarkers have been 
      identified, their implementation in clinical practice has so far remained largely 
      unsuccessful. Whereas cardiac-specific biomarkers, including natriuretic peptides 
      (ANP and BNP) and high sensitivity troponins (hsTn), are widely used in clinical 
      practice, other biomarkers have not yet proven their utility. Galectin-3 (Gal-3) 
      and soluble suppression of tumorigenicity 2 (sST2) are the only novel HF 
      biomarkers that are included in the ACC/AHA HF guidelines, but their clinical 
      utility still needs to be demonstrated. In this review, we will describe 
      natriuretic peptides, hsTn, and novel HF biomarkers, including Gal-3, sST2, human 
      epididymis protein 4 (HE4), insulin-like growth factor-binding protein 7 
      (IGFBP-7), heart fatty acid-binding protein (H-FABP), soluble CD146 (sCD146), 
      interleukin-6 (IL-6), growth differentiation factor 15 (GDF-15), procalcitonin 
      (PCT), adrenomedullin (ADM), microRNAs (miRNAs), and metabolites like 
      5-oxoproline. We will discuss the biology of these HF biomarkers and conclude 
      that most of them are markers of general pathological processes like fibrosis, 
      cell death, and inflammation, and are not cardiac- or HF-specific. These 
      characteristics explain to a large degree why it has been difficult to relate 
      these biomarkers to a single disease. We propose that, in addition to clinical 
      investigations, it will be pivotal to perform comprehensive preclinical biomarker 
      investigations in animal models of HF in order to fully reveal the potential of 
      these novel HF biomarkers.
FAU - Piek, Arnold
AU  - Piek A
AD  - a Department of Cardiology , University Medical Center Groningen, University of 
      Groningen , Groningen , The Netherlands.
FAU - Du, Weijie
AU  - Du W
AD  - a Department of Cardiology , University Medical Center Groningen, University of 
      Groningen , Groningen , The Netherlands.
AD  - b Department of Pharmacology, College of Pharmacy , Harbin Medical University , 
      Harbin , China.
FAU - de Boer, Rudolf A
AU  - de Boer RA
AUID- ORCID: 0000-0002-4775-9140
AD  - a Department of Cardiology , University Medical Center Groningen, University of 
      Groningen , Groningen , The Netherlands.
FAU - Sillje, Herman H W
AU  - Sillje HHW
AD  - a Department of Cardiology , University Medical Center Groningen, University of 
      Groningen , Groningen , The Netherlands.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20180417
PL  - England
TA  - Crit Rev Clin Lab Sci
JT  - Critical reviews in clinical laboratory sciences
JID - 8914816
RN  - 0 (Biomarkers)
RN  - 0 (Blood Proteins)
RN  - 0 (Galectin 3)
RN  - 0 (Galectins)
RN  - 0 (LGALS3 protein, human)
RN  - 0 (Natriuretic Peptides)
RN  - 0 (Troponin)
SB  - IM
MH  - Animals
MH  - Biomarkers/*blood
MH  - Blood Proteins
MH  - Cell Death
MH  - Disease Models, Animal
MH  - Galectin 3/blood
MH  - Galectins
MH  - Heart Failure/*blood/*diagnosis/metabolism
MH  - Humans
MH  - Inflammation
MH  - Natriuretic Peptides/blood
MH  - Troponin/blood
OTO - NOTNLM
OT  - Biomarkers
OT  - cell death
OT  - fibrosis
OT  - heart failure
OT  - inflammation
EDAT- 2018/04/18 06:00
MHDA- 2019/02/08 06:00
CRDT- 2018/04/18 06:00
PHST- 2018/04/18 06:00 [pubmed]
PHST- 2019/02/08 06:00 [medline]
PHST- 2018/04/18 06:00 [entrez]
AID - 10.1080/10408363.2018.1460576 [doi]
PST - ppublish
SO  - Crit Rev Clin Lab Sci. 2018 Jun;55(4):246-263. doi: 
      10.1080/10408363.2018.1460576. Epub 2018 Apr 17.